At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 16 enrolled
Drug / intervention
Baricitinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pharmacokinetic Study of Baricitinib in Subjects With Hepatic Dysfunction
In Brief
A Phase 1 clinical trial evaluating Baricitinib for Liver Diseases and Hepatic Insufficiency. Completed, enrolled 16 participants across 2 sites.
Detailed Summary
The main purpose of this study is to measure how much of the study drug called baricitinib gets into the blood stream and how long it takes the body to get rid of it. Healthy participants and those with liver disease may enroll. The study will last about 7 days for each participant, not including screening.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLiver Diseases, Hepatic Insufficiency
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartJun 2013
First PostedJun 2013
Primary CompletionJul 2013
TodayJul 2026
First PostedJun 6, 2013
Enrollment StartJun 1, 2013
Primary CompletionJul 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 13.1 years ago
Interventions
Baricitinibdrug
Administered orally